A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 307-311

  Akerley, Wallace ^a,b,d   Boucher, Kenneth ^a,d   Rich, Nathan ^c,d   Egbert, Lyle ^a,d   Harker, Graydon ^c,d   Bylund, Julie ^a,b,d   Van Duren, Terry ^a   Reddy, Chakravarthy ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c INTERMOUNTAIN HEALTHCARE   (United States)

^d Huntsman Intermountain Cancer Care Program   (United States)

Author keywords

Bevacizumab; Chemotherapy; EGFR mutation; Erlotinib; Lung cancer; Serum proteomic evaluation

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; ERLOTINIB; LOPERAMIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DIARRHEA; DRUG ERUPTION; EPISTAXIS; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NON SQUAMOUS NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PAIN; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT CANCER; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PROTEINS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEOMICS; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 84873164498     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.005     Document Type: Article

References (25)

1. Thun J., Jemal A., Siegel R., et al. Cancer Statistics 2007. CA Cancer J Clin 2007, 57:43-66.
2. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18(10):2095-2103.
3. Rapp E., Pater J.L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988, 6(4):633-641.
4. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18(12):2354-2362.
5. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
6. Sweeney C.J., Zhu J., Sandler A.B., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001, 92(10):2639-2647.
7. Wassenaar T.R., Eickhoff J.C., Jarzemsky D.R., et al. Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer. J Thorac Oncol 2007, 2(August (8)):722-728.
8. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(July (2)):123-132.
9. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
10. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
11. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for Non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
12. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
13. Herbst R.S., O'Neill V.J., Fehrenbacher L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007, 25(October (30)):4743-4750.
14. Schicher N., Paulitschke V., Swoboda A., et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009, 15:3495-3502.
15. Wu W., Onn A., Isobe T., et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007, 6:471-483.
16. Herbst R.S., Ansari R., Bustin F., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377(May (9780)):1846-1854.
17. Taguchi F., Solomon B., Gregorc V., et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99:838-846.
18. Carbone D.P., Ding K., Roder H., et al. Prognostic and predictive role of the Veristrat Plasma Test in patients with advanced non-small cell lung cancer treated with erlotinib or placebo in the NCIC clinical trials group BR.21 Trial. J Thorac Oncol 2012, 7:1653-1660.
19. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000, 92(3):205-216.
20. Akerley W., Boucher K.M., Bentz J.S., et al. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol 2009, 4(February (2)):214-219.
21. Lilenbaum R., Axelrod R., Thomas S., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008, 26(6):863-869.
22. Lee S., Rudd R., Khan I., et al. TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010, 28:15s. (suppl; abstr 7504).
23. Gridelli C., Ciardiello F., Feld R., et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer: The TORCH trial. J Clin Oncol 2010, 28:15s. (suppl; abstr 7508).
24. Carbone D.P., Salmon J.S., Billheimer D., et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010, 69:337-340.
25. Amann J., Lee J.W., Roder H., et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010, 5(2):169-178.